EXHIBIT 10.20
-------------
LETTER AGREEMENT
----------------
1. BACKGROUND
----------
a. Isolyser Company, Inc., a Georgia corporation, having its principal
place of business at ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇., ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇
("Isolyser"), and Allegiance Healthcare Corporation, a Delaware corporation
having its principal place of business at ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇,
▇▇▇▇▇▇▇▇ ▇▇▇▇▇, and its affiliates (collectively referred to as "Allegiance")
entered into a Supply and License Agreement effective July 12, 1999 (the
"Agreement").
b. Isolyser has developed proprietary rights in the manufacture and sale
of certain products which is sold under the OREX(R) trademark, all of which are
manufactured from Isolyser's proprietary degradable polyvinyl alcohol ("PVA") or
novel dispersal polymers ("NDP") material which can be dissolved and then
disposed via normal sanitary sewer systems ("Material").
c. Isolyser desired to expand its commercial opportunities through the
manufacture and sale of the Material to Allegiance and by licensing to
Allegiance the Patents and Trademarks relating to the right to make, use,
distribute, sell and dispose healthcare products made from the Material
("Products").
d. Isolyser, under the terms of the Agreement granted to Allegiance a
worldwide exclusive license to make, use and sell Products embodying or made in
accordance with the inventions claimed in the Patents within and for healthcare
applications. The Agreement defined a term and certain rights and obligations of
the parties.
2. ISOLYSER ACKNOWLEDGES
---------------------
Isolyser acknowledges that:
a. Allegiance has met all of its obligations and responsibilities under
the Agreement to date; and
b. Allegiance is unable to fulfill the remainder of its requirements
under the Agreement, and accordingly, is not required to do so, until such
time as Isolyser meets its obligations under the Agreement and achieves the
success criteria delineated in Section 4 including, without limitation,
developing a fully operational economically feasible backend processor,
obtaining all regulatory approvals for all disposable and/or dispersible
Materials, and provision on a timely basis of quality materials that
consistently meet specifications.
3. TRANSITION PERIOD
-----------------
In order to provide Isolyser with an additional opportunity to complete its
product and systems development and on the basis that both parties would like to
have a beneficial relationship, the parties agree as follows:
a. As used herein, the term "Transition Period" shall mean the period of
time beginning on the date this Letter Agreement is last executed by the parties
hereto and ending on the earlier of December 31, 2001 or such date as Isolyser
and Allegiance agree in their discretion that all product and systems
development efforts related to the Products have been satisfactorily completed.
b. All rights related to Allegiance's exclusive license will remain in
full force and effect during the Transition Period.
c. Allegiance will have no further obligations to purchase Material or
provide additional sales, marketing or promotional support or make any further
investments during the Transition Period except as set forth in 3h below.
d. During the Transition Period both parties agree to evaluate design and
material requirements consistent with the appropriate economic models and
environmental benefits.
e. During the period commencing on the date Allegiance countersigns this
letter agreement and continuing until June 30, 2001, Allegiance will accept one
order from Isolyser under which Allegiance will manufacture Products, provided
that the quantity of Product ordered must be agreed upon by the parties based on
on-hand inventory, customer demand and anticipated start date of Isolyser's
alternative operations. Isolyser will use commercially reasonable efforts to
quickly establish its converting operations.
f. Isolyser and Allegiance will jointly visit already established
customer accounts (the "Founder Accounts") listed on Schedule 1 attached hereto
and incorporated herein to explain the difficulties related to raw materials,
processing technology and economic viability.
g. During the Transition Period the Founder Accounts will make their
product selections/substitutions for the Transition Period.
h. Isolyser and Allegiance will develop a transition plan for each
customer in an effort to minimize the impact to that customer. During the
Transition Period, Allegiance will distribute Products to a limited number of
Founder Accounts agreed upon by Allegiance.
Isolyser will use commercially reasonable efforts to complete the development of
a satisfactory backend processor.
4. SUCCESS CRITERIA
----------------
The parties have further agreed that the criteria for success to determine
if Allegiance will once again begin efforts to launch the Product line are as
follows:
a. The backend processor must be functioning, reliable and affordable.
b. Raw material must meet specifications and be free from contamination.
Isolyser will continue with development toward a three meter finished roll stock
and will explore more economic alternatives to the current raw material
available.
c. POTW approvals, present and future will cover any and all
dissolvable/dispersible materials (PVA, NDP or other) used in the Product line.
d. Both parties will agree to an acceptable rate of return for their
respective businesses. The metric for measurement and the acceptable ranges have
yet to be determined.
e. Three mutually agreed-upon customers will be using the Product line
and will be processing the Products without issue for a period of 90 days. The
economic model which is applied must demonstrate a position of cost neutrality
for the customer.
f. At such point in time the entire program (from raw material to backend
processing) has been deemed successful, the parties will review and evaluate all
options related to converting, which may include moving the conversion back to
Allegiance Convertors, or converting in China with the GRI operation.
At regular intervals during the Transition Period and upon expiration of
the Transition Period, the parties will meet and evaluate the status of the
Success Criteria or agree to a new form of mutually acceptable agreement which
more accurately reflects the realities of the entire program and the
then-current relationship between Allegiance and Isolyser.
ALLEGIANCE HEALTHCARE CORPORATION ISOLYSER COMPANY, INC.
By:____________________________ By:______________________________
Title:_________________________ Title:___________________________
Date:__________________________ Date: ___________________________